clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-121Research ArticleНОВЫЕ МЕДИЦИНСКИЕ ТЕХНОЛОГИИNEW HEALTH TECHNOLOGYУроки, полученные за 60 лет фармацевтических инноваций: рефератMunosBernard201005062018011115Copyright © Munos B., 20182018Munos B.Munos B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/121разработка лекарствстоимость разработки лекарствновые малые молекулыdrug developingcostsR&Dновые молекулярные единицыReferences.Anthony S. D. Can you spot the early warnings? Strategy & Innovation 3, no . 2 (March/April 2005) ..Anthony S. D. Can you spot the early warnings? Strategy & Innovation 3, no . 2 (March/April 2005) ..Arias E. United States Life Tables, 2004 . National Center for Health Statistics website (2004).Arias E. United States Life Tables, 2004 . National Center for Health Statistics website (2004).Burrill & Company . Biotech 2008: a 20/20 vision to 2020 . Available from the BayBio website (2008) ..Burrill & Company . Biotech 2008: a 20/20 vision to 2020 . Available from the BayBio website (2008) ..Christensen C. Seeing What’s Next: Using Theories of Innovation to Predict Industry Change (Harvard Business School Press, Boston, Massachusetts, 2004) ..Christensen C. Seeing What’s Next: Using Theories of Innovation to Predict Industry Change (Harvard Business School Press, Boston, Massachusetts, 2004) ..De Vany A. Hollywood Economics: How Extreme Uncertainty Shapes the Film Industry (Routledge, London, 2003) ..De Vany A. Hollywood Economics: How Extreme Uncertainty Shapes the Film Industry (Routledge, London, 2003) ..DiMasi J. A., Grabowski H. G. The cost of biopharmaceutical R&D . Manage . Decis . Econ . 28, 469–479 (2007) ..DiMasi J. A., Grabowski H. G. The cost of biopharmaceutical R&D . Manage . Decis . Econ . 28, 469–479 (2007) ..Grabowski H. G. & Kyle M. in The Economics of Corporate Governance and Mergers (eds Gugler K . & Yurtoglu B .) 262–287 (Edward Elgar, Cheltenham, 2008) ..Grabowski H. G. & Kyle M. in The Economics of Corporate Governance and Mergers (eds Gugler K . & Yurtoglu B .) 262–287 (Edward Elgar, Cheltenham, 2008) ..Grabowski H. G., Vernon J. M. & Thomas L. G. Estimating the effects of regulation on international innovation . J . Law Econ . 21, 133–163 (1978) ..Grabowski H. G., Vernon J. M. & Thomas L. G. Estimating the effects of regulation on international innovation . J . Law Econ . 21, 133–163 (1978) ..Hartung A. Create Marketplace Disruption (FT Press, Upper Saddle River, 2008) ..Hartung A. Create Marketplace Disruption (FT Press, Upper Saddle River, 2008) ..Jack A. An acute talent for innovation . Financial Times (2 Feb 2009) ..Jack A. An acute talent for innovation . Financial Times (2 Feb 2009) ..National Academy of Engineering . The Competitive Status of the U . S . Pharmaceutical Industry (National Academies Press, Washington, 1983) ..National Academy of Engineering . The Competitive Status of the U . S . Pharmaceutical Industry (National Academies Press, Washington, 1983) ..PhRMA . Pharmaceutical Industry Profile 2009 . PhRMA website (2009) ..PhRMA . Pharmaceutical Industry Profile 2009 . PhRMA website (2009) ..Stoeffels P. Collaborative innovation for the post-crisis world . Boston Globe (2 Feb 2009) ..Stoeffels P. Collaborative innovation for the post-crisis world . Boston Globe (2 Feb 2009) ..Taleb N. The Black Swan: The Impact of the Highly Improbable (Random House, London, 2007) ..Taleb N. The Black Swan: The Impact of the Highly Improbable (Random House, London, 2007) ..Wiggins S. N. The Cost of Developing a New Drug (Pharmaceutical Manufacturers Association, Washington, 1987) ..Wiggins S. N. The Cost of Developing a New Drug (Pharmaceutical Manufacturers Association, Washington, 1987) .
The authors declare that there are no conflicts of interest present.